Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 90,900 shares, a decrease of 21.6% from the August 15th total of 115,900 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily trading volume, of 496,100 shares, the short-interest ratio is currently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Tenax Therapeutics in a report on Tuesday, September 10th. They set a “sell” rating on the stock.
Check Out Our Latest Analysis on TENX
Tenax Therapeutics Trading Down 0.8 %
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. As a group, research analysts anticipate that Tenax Therapeutics will post -6.68 EPS for the current year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What is Insider Trading? What You Can Learn from Insider Trading
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.